MEREO BIOPHARMA GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.03 USD | -7.34% |
|
-7.06% | +31.17% |
Presenter SpeechDenise Scots-Knight (Executives)Good morning. My name is Denise Scots-Knight, ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Calendar
2024-09-16
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.421
GBP
Average target price
4.977
GBP
Spread / Average Target
+105.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.17% | 424M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- MREO Stock
- News Mereo BioPharma Group plc
- Transcript : Mereo BioPharma Group plc - Special Call
